Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors

被引：0
|
作者：
Yasaman Ardeshirpour
Dan L. Sackett
Jay R. Knutson
Amir H. Gandjbakhche
机构：
[1] Section on Analytical and Functional Biophotonics,
[2] NICHD,undefined
[3] NIH,undefined
[4] Division of Basic and Translational Biophysics,undefined
[5] NICHD,undefined
[6] NIH,undefined
[7] Laboratory of Advanced Microscopy and Biophotonics,undefined
[8] NHLBI,undefined
来源：
EJNMMI Research | / 8卷
关键词：
Fluorescence lifetime imaging; Fluorescent biomarkers; Human epidermal growth factor 2 receptor; HER2 receptor; Affibody probe;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors
    Ardeshirpour, Yasaman
    Sackett, Dan L.
    Knutson, Jay R.
    Gandjbakhche, Amir H.
    EJNMMI RESEARCH, 2018, 8
  • [2] Imaging and therapeutic targeting of HER2-positive tumors using Affibody molecules
    Nilsson, Fredrik Y.
    Orlova, Anna
    Tolmachev, Vladimir
    Lundqvist, Hans
    Carlsson, Jorgen
    Widstrom, Charles
    Sandstrom, Mattias
    Pehrson, Rikard
    Stahl, Stefan
    Wennborg, Anders
    Wennborg, Anders
    Feldwisch, Joachim
    CANCER RESEARCH, 2006, 66 (08)
  • [3] Affibody molecules for in vivo characterization of HER2-positive tumors by near-infrared imaging
    Lee, Sang Bong
    Hassan, Moinuddin
    Fisher, Robert
    Chertov, Oleg
    Chernomordik, Victor
    Kramer-Marek, Gabriela
    Gandjbakhche, Amir
    Capala, Jacek
    CLINICAL CANCER RESEARCH, 2008, 14 (12) : 3840 - 3849
  • [4] Nanographene oxide-based radioimmunoconstructs for in vivo targeting and SPECT imaging of HER2-positive tumors
    Cornelissen, Bart
    Able, Sarah
    Kersemans, Veerle
    Waghorn, Philip A.
    Myhra, Sverre
    Jurkshat, Kerstin
    Crossley, Alison
    Vallis, Katherine A.
    BIOMATERIALS, 2013, 34 (04) : 1146 - 1154
  • [5] In Vivo Assessment of HER2 Receptor Density in HER2-positive Tumors by Near-infrared Imaging, Using Repeated Injections of the Fluorescent Probe
    Ardeshirpour, Yasaman
    Hassan, Moinuddin
    Zielinski, Rafal
    Horton, Jason A.
    Capala, Jacek
    Gandjbakhche, Amir H.
    Chernomordik, Victor
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2014, 13 (05) : 427 - 434
  • [6] All HER2-Positive Tumors are not Created Equal
    Elizabeth A. Mittendorf
    Mariana Chavez-MacGregor
    Annals of Surgical Oncology, 2017, 24 : 3471 - 3474
  • [7] All HER2-Positive Tumors are not Created Equal
    Mittendorf, Elizabeth A.
    Chavez-MacGregor, Mariana
    ANNALS OF SURGICAL ONCOLOGY, 2017, 24 (12) : 3471 - 3474
  • [8] New ADC Shrinks HER2-Positive Tumors
    Leslie, Mitch
    CANCER DISCOVERY, 2019, 9 (09) : 1151 - 1152
  • [9] Immunotherapy for HER2-positive medulloblastoma: Regression of experimental tumors by transfer of HER2-redirected T cells in vivo
    Ahmed, N. M.
    Ratnayake, M. K.
    Savoldo, B.
    Perlaky, L.
    Dotti, G. P.
    Wels, W.
    Bhattacharjee, M. B.
    Shine, H. D.
    Rooney, C. M.
    Heslop, H. E.
    Gottschalk, S.
    NEURO-ONCOLOGY, 2007, 9 (02) : 196 - 196
  • [10] Immunotherapy for Her2-Positive Medulloblastoma: Regression of Experimental Tumors by Transfer of Her2-Redirected T Cells In Vivo
    Ahmed, Nabil M.
    Ratnayake, Maheshika K.
    Savoldo, Barbara
    Perlaky, Laszlo
    Dotti, Gianpietro
    Wels, Winfried
    Bhattacharjee, Meenakshi B.
    Shine, H. David
    Rooney, Cliona M.
    Heslop, Helen E.
    Gottschalk, Stephen
    MOLECULAR THERAPY, 2006, 13 : S296 - S296
12345